Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.43 |
| ▸ | METAP1 | P53582 | 1/20 | 0.42 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.41 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | TTK | P33981 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30914163 | 0.86 | PDK1 (0.57) | NLRP3PDK1PDK2PDK3PDK4 | |
| SCHEMBL24110547 | 0.86 | LMNA (0.48) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL4774446 | 0.86 | PDK1 (0.57) | NLRP3PDK1PDK2PDK3PDK4 | |
| SCHEMBL2880191 | 0.84 | LMNA (0.54) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL7043141 | 0.82 | LMNA (0.45) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL17522467 | 0.81 | MEN1 (0.52) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL17521618 | 0.79 | GAA (0.43) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL1534089 | 0.78 | NPC1 (0.58) | LMNAPOLBRXFP1BRD9PDK1 | |
| SCHEMBL2880194 | 0.78 | BRD9 (0.52) | LMNAPOLBRXFP1BRD9METAP1 | |
| SCHEMBL736662 | 0.78 | POLB (0.49) | LMNAPOLBRXFP1BRD9METAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2206704-A1 | Pharmaceutically active diazepanes | Novartis AG (CH) | 2010-07-14 | — | — | EP | claimed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | claimed |
| CN-101163685-A | Pharmaceutically active diazepanes | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-16 | — | — | CN | claimed |
| EP-1874739-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | Novartis AG (CH) | 2008-01-09 | — | — | EP | claimed |
| WO-2006111371-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2006-10-26 | — | — | WO | claimed |
| EP-2206704-A1 | Pharmaceutically active diazepanes | Novartis AG (CH) | 2010-07-14 | — | — | EP | disclosed |
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | OBERHAUSER BERNDT | 2008-12-04 | — | — | US | disclosed |
| CN-101163685-A | Pharmaceutically active diazepanes | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-16 | — | — | CN | disclosed |
| EP-1874739-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| WO-2006111371-A1 | PHARMACEUTICALLY ACTIVE DIAZEPANES | NOVARTIS AG (CH) | 2006-10-26 | — | — | WO | disclosed |
| CN-1723199-A | 1,4-disubstituted piperidine derivatives and their use as 11-beta hsd1 inhibitors | ASTRAZENECA AB (SE) | 2006-01-18 | — | — | CN | disclosed |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | ASTRAZENECA AB (SE) | 2005-11-17 | — | — | US | disclosed |
| EP-1556349-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | Astrazeneca AB (SE) | 2005-07-27 | — | — | EP | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300237-A1 | Pharmaceutically Active Diazepanes | VCAM1, ICAM1, CD69 | LMNA 3812/4885POLB 4451/4885RXFP1 2333/4885 |
| US-20050256159-A1 | 1,4-disubstituted piperidine derivatives and their use as 11,betahsd1 inhibitors | HSD11B1, HSD3B1, P4HA1 | LMNA 3152/4885POLB 1926/4885RXFP1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.